Number of Patients Studied Prior to Approval of New Medicines: A Database Analysis

PLoS Medicine

Volumn 10, Issue 3, 2013, Pages

  Duijnhoven, Ruben G ^a,b   Straus, Sabine M J M ^b,c   Raine, June M ^d   de Boer, Anthonius ^a   Hoes, Arno W ^e   de Bruin, Marie L ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b MEDICINES EVALUATION BOARD   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ORPHAN DRUG;

ASTHMA; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; HUMAN; PATIENT; PATIENT SAFETY; REVIEW; SAMPLE SIZE;

CHRONIC DISEASE; DATABASES, FACTUAL; DRUG APPROVAL; HUMANS; MARKETING; PATIENT PARTICIPATION; SAMPLE SIZE; TIME FACTORS;

EID: 84875425022     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001407     Document Type: Review

References (40)

1. Stricker BH, Psaty BM, (2004) Detection, verification, and quantification of adverse drug reactions. BMJ 329: 44-47.
2. Barbour V, Clark J, Jones S, Norton M, Simpson P, et al. (2011) Why drug safety should not take a back seat to efficacy. PLoS Med 8: e1001097 doi:10.1371/journal.pmed.1001097.
3. Vandenbroucke JP, Psaty BM, (2008) Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. JAMA 300: 2417-2419.
4. Committee for Proprietary Medicinal Products (1994) ICH topic E 1-population exposure: the extent of population exposure to assess clinical safety. CPMP/ICH/375/95. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002747.pdf. Accessed 8 February 2013.
5. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (1994) ICH harmonised tripartite guideline: the extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions-E1. Available: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E1/Step4/E1_Guideline.pdf. Accessed 8 February 2013.
6. European Commission Directorate-General Health and Consumers (2013) Community register of medicinal products. Available: http://ec.europa.eu/health/documents/community-register/html/index_en.htm. Accessed 4 February 2013.
7. European Medicines Agency (2013) European public assessment reports. Available: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d125. Accessed 4 February 2013.
8. Rawlins MD, Jefferys DB, (1991) Study of United Kingdom product licence applications containing new active substances, 1987-9. BMJ 302: 223-225.
9. Nissen SE, Wolski K, (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471.
10. Woodcock J, Sharfstein JM, Hamburg M, (2010) Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. N Engl J Med 363: 1489-1491.
11. Eichler HG, Pignatti F, Flamion B, Leufkens H, Breckenridge A, (2008) Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nat Rev Drug Discov 7: 818-826.
12. Eichler HG, Abadie E, Raine JM, Salmonson T, (2009) Safe drugs and the cost of good intentions. N Engl J Med 360: 1378-1380.
13. Breckenridge A, Walley T, (2008) Early access to new medicines. Clin Pharmacol Ther 84: 23-25.
14. Breckenridge A, Woods K, Raine J, (2005) Monitoring the safety of licensed medicines. Nat Rev Drug Discov 4: 541-543.
15. Raine J, Wise L, Blackburn S, Eichler HG, Breckenridge A, (2011) European perspective on risk management and drug safety. Clin Pharmacol Ther 89: 650-654.
16. Avorn J, (2006) Evaluating drug effects in the post-Vioxx world: there must be a better way. Circulation 113: 2173-2176.
17. Brewer T, Colditz GA, Brewer T, (1999) Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 281: 824-829.
18. Hauben M, Aronson JK, (2007) Gold standards in pharmacovigilance-the use of definitive anecdotal reports of adverse drug reactions as pure gold and high-grade ore. Drug Saf 30: 645-655.
19. Waller PC, Evans SJ, (2003) A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 12: 17-29.
20. Mini-Sentinel Coordinating Center (2011) Welcome to Mini-Sentinel. Available: http://www.mini-sentinel.org/. Accessed 4 February 2013.
21. US Food and Drug Administration (2013) FDA's Sentinel Initiative. Available: http://www.fda.gov/Safety/FDAsSentinelInitiative/default.htm. Accessed 4 February 2013.
22. EU-ADR (2013) Welcome to the EU-ADR website. Available: http://www.alert-project.org/. Accessed 4 February 2013.
23. Avorn J, Schneeweiss S, (2009) Managing drug-risk information-what to do with all those new numbers. N Engl J Med 361: 647-649.
24. Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, et al. (2011) Developing the Sentinel System-a national resource for evidence development. N Engl J Med 364: 498-499.
25. Coloma PM, Schuemie MJ, Trifirò G, Gini R, Herings R, et al. (2010) Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf 20: 1-11.
26. Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. (2004) Available: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2004:136:0001:0033:EN:PDF. Accessed 8 February 2013.
27. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. (2001) Available: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2001:311:0067:0128:EN:PDF. Accessed 8 February 2013.
28. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2002) ICH harmonised tripartite guideline: Pharmacovigilance Planning-E2E. Available: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2E/Step4/E2E_Guideline.pdf. Accessed 8 February 2013.
29. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. (2004) Available: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2004:136:0034:0057:EN:PDF. Accessed 8 February 2013.
30. Heads of Medicines Agencies, European Medicines Agency (2012) Guideline on good pharmacovigilance practices (GVP): module V-risk management systems. EMA/838713/2011. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129134.pdf. Accessed 11 February 2013.
31. US Food and Drug Administration Amendments Act of 2007. (2007) Available: http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf. Accessed 11 February 2013.
32. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research (2011) Guidance for industry: postmarketing studies and clinical trials-implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act. Available: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM172001.pdf. Accessed 11 February 2013.
33. Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010. (2010) Amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products. Available: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0001:0016:EN:PDF. Accessed 11 February 2013.
34. Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use. (2010) Available: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0074:0099:EN:PDF. Accessed 11 February 2013.
35. Blake KV, Prilla S, Accadebled S, Guimier M, Biscaro M, et al. (2011) European Medicines Agency review of post-authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Pharmacoepidemiol Drug Saf 20: 1021-1029.
36. Waller P, (2011) Getting to grips with the new European Union pharmacovigilance legislation. Pharmacoepidemiol Drug Saf 20: 544-549.
37. Eichler HG, Oye K, Baird LG, Abadie E, Brown J, et al. (2012) Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther 91: 426-437.
38. Woodcock J, (2012) Evidence vs. access: can twenty-first-century drug regulation refine the tradeoffs? Clin Pharmacol Ther 91: 378-380.
39. Eichler HG, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, et al. (2011) Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response. Nat Rev Drug Discov 10: 495-506.
40. Staa TP, Goldacre B, Gulliford M, Cassell J, Pirmohamed M, et al. (2012) Pragmatic randomised trials using routine electronic health records: putting them to the test. BMJ 344: e55.